ZBIO

Zenas BioPharma, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$27.64

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %39 / %30

Non-compliant assets / Total market cap %45.9 / %30

Non-compliant revenue / Total income %58.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.

Website

Analysis (Turkish): ZBIO Hissesi Caiz mi, Helal mi? Zenas BioPharma, Inc. Katılım Analizi